Suchergebnisse - "Pour, Luděk"

PubPharm (225)

1

ANCHOR : melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

enthalten in: Haematologica | 2024

von Ocio, E. | Efebera, Y. | Hájek, R. | +12

2

Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma : results from the randomized, open-label, phase III LIGHTHOUSE study

enthalten in: Haematologica | 2024

von Pour, L. | Szarejko, M. | Bila, J. | +13

3

Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone : analyses from the phase III OCEAN study

enthalten in: Haematologica | 2024

von Schjesvold, F. | Ludwig, H. | Delimpasi, S. | +15

4

PORT : A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Pour, L. | Micheva, I. | Usenko, G. | +8

5

Isoelectric focusing followed by affinity immunoblotting to detect monoclonal free light chains in monoclonal gammopathies : Comparison with immunofixation electrophoresis and free light chain ratio

enthalten in: Annals of clinical biochemistry | 2024

von Zeman, D. | Štork, M. | Švancarová, L. | +5

6

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

7

Improved Screening of Monoclonal Gammopathy Patients by MALDI-TOF Mass Spectrometry

enthalten in: Journal of the American Society for Mass Spectrometry | 2023

von Pečinka, L. | Vlachová, M. | Moráň, L. | +9

8

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129) : final analysis of a non-randomised, multicentre, phase 2 study

enthalten in: The Lancet. Oncology | 2023

von van de Donk, N. | Minnema, M. | van der Holt, B. | +25

9

Correction : Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

enthalten in: Blood cancer journal | 2023

von Martin, T. | Dimopoulos, M. | Mikhael, J. | +18

ErratumFor: Blood Cancer J. 2023 May 9;13(1):72. - PMID 37156782

10

Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients : An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Bringhen, S. | Pour, L. | Benjamin, R. | +11

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[23]